Psychopharmacology

Antidepressant withdrawal often mimics relapse; learn why hyperbolic tapering, informed consent, and slow cut-and-hold deprescribing reduce harm.

Cognition extends zervimesine expanded access for Lewy body dementia, adding months of dosing and easier local monitoring.

Long-term antidepressant use rises in Australia, surging among individuals aged 10 to 24, with more off-label sleep and pain prescribing raising safety and withdrawal concerns.

Preclinical mGlu7 negative allosteric modulator ADX71743 disrupts fear-memory reconsolidation.

In response to the APA’s roadmap for the future DSM, John J. Miller, MD, examines how its rigid diagnostic categories may limit clinicians’ ability to deliver care.

Explore the complexities of psychopharmacology in treating personality disorders, focusing on symptom management and the importance of therapeutic alliances.

Neurocrine Biosciences launches a phase 2 trial for NBI-1065890.

LPCN 1154 shows promise as a rapid, at-home treatment for postpartum depression, with favorable safety results in ongoing phase 3 trials.

Tim Wilens, MD, discussed mechanism of action and efficacy of new medications at APSARD Conference.

Timothy Wilens, MD, shares highlights and clinical implications for ADHD from the APSARD Annual Conference.

Review the misperceptions patients and clinicians may have about ADHD diagnosis and treatment.

Clinicians explore the complex relationship between ADHD medication and pregnancy, emphasizing individualized risk assessments for optimal maternal and child health.

Poster discusses evidence-based strategies for managing adult ADHD, including medication guidelines and considerations for comorbid conditions.

Centanafadine demonstrates promising effects on ADHD symptoms, enhancing key neurotransmitters without increasing psychomotor activity, according to poster data.

Cobenfy's innovative approach to treating schizophrenia marks a significant shift in psychiatric care.

Explore the unique mood-stabilizing properties of antiepileptics like lamotrigine, valproic acid, and carbamazepine in bipolar disorder treatment.

A clinical trial reveals challenges in assessing schizophrenia symptoms due to cultural and language differences, highlighting the need for improved measurement tools.

NTX-253 enters phase 1 trials, exploring a novel approach to schizophrenia treatment with potential for improved safety and efficacy.

Acceptance paves the way for a critical trial of COMP360, a synthetic psilocybin that has the potential to transform PTSD care.

Cognition Therapeutics shares zervimesine's promising phase 2 results, showing safety and improved symptoms in dementia with Lewy bodies.

Xanomeline/trospium emerges as a groundbreaking schizophrenia treatment, showcasing efficacy and safety while highlighting challenges in clinical adoption.

Discover groundbreaking findings on digital therapeutics and medications for schizophrenia and depression, showcasing safety and efficacy in recent studies.

Syremis Therapeutics advances innovative drugs ST-905 and ST-901 for schizophrenia and major depressive disorder, aiming to transform mental health treatment.

Cobenfy gains NMPA approval in China, offering a groundbreaking treatment for schizophrenia with a unique mechanism and improved symptom management.